Pediatric Adrenal Insufficiency (Addison Disease)
- Author: Phyllis W Speiser, MD; Chief Editor: Stephen Kemp, MD, PhD more...
Background
Adrenal insufficiency (Addison disease) can be classified as primary, which occurs when the adrenal gland itself is dysfunctional, or secondary, also called central adrenal insufficiency, which occurs when a lack of secretion of corticotropin-releasing hormone (CRH) from the hypothalamus or of adrenocorticotropic hormone (ACTH) from the pituitary leads to hypofunction of the adrenal cortex. See the image below.
Regulation of the adrenal cortex. ACTH = adrenocorticotropic hormone; CRF = corticotropin-releasing factor; neg. = negative. Adrenal insufficiency (Addison disease) can further be classified as congenital or acquired (see Etiology).
See also Addison Disease (Adrenal Insufficiency).
Anatomy
The adrenal cortex is divided into 3 major anatomic zones. The zona glomerulosa produces aldosterone, and the zonae fasciculata and reticularis together produce cortisol and adrenal androgens. A fetal zone, unique to primates, produces dehydroepiandrosterone (DHEA), a precursor of both androgens and estrogens. This zone involutes within the first few months of postnatal life.
Aldosterone secretion is primarily regulated by the renin-angiotensin system. Increased serum potassium concentrations can also stimulate aldosterone secretion. Cortisol secretion is regulated by adrenocorticotropic hormone (ACTH), which, in turn, is regulated by corticotropin-releasing hormone (CRH) from the hypothalamus. Serum cortisol inhibits the secretion of both CRH and ACTH to prevent excessive secretion of cortisol from the adrenal glands.
ACTH partially regulates adrenal androgen secretion; other unknown factors contribute to this regulation as well. ACTH not only stimulates cortisol secretion but also promotes growth of the adrenal cortex in conjunction with growth factors such as insulinlike growth factor (IGF)-1 and IGF-2.[1]
Etiology
Iatrogenic central adrenal insufficiency (Addison disease) as well as acquired and congenital primary adrenal insufficiency (Addison disease) are briefly discussed in this section.
Iatrogenic central adrenal insufficiency
Most cases of adrenal insufficiency (Addison disease) are iatrogenic, caused by long-term administration of glucocorticoids. A mere 2 weeks' exposure to pharmacologic doses of glucocorticoids can suppress the corticotropin-releasing hormone (CRH)–adrenocorticotropic hormone (ACTH)–adrenal axis. The suppression can be so great that acute withdrawal or stress may prevent the axis from responding with sufficient cortisol production to prevent an acute adrenal crisis.
Treatment with megestrol acetate, an orexigenic agent, has also resulted in iatrogenic adrenal suppression. The mechanism is presumably related to the glucocorticoid properties of megestrol acetate.[2]
Other causes of central adrenal insufficiency (Addison disease) include congenital or acquired hypopituitarism and ACTH unresponsiveness. This unresponsiveness may be isolated (as in Familial Glucocorticoid Deficiency) (Online Mendelian Inheritance in Man database [OMIM] 202200),[3, 4] or it may be associated with achalasia and alacrima (as in achalasia-addisonism-alacrima syndrome, or triple A syndrome [AAAS]) (OMIM 231550).[5, 6]
Acquired primary adrenal insufficiency
In developed countries, the most common cause of adrenal insufficiency (Addison disease) is autoimmune destruction of the adrenal cortex.[7] This disorder may occur in isolation or may be part of a polyglandular autoimmune disorder (PGAD).
Patients with type 1 PGAD (OMIM 240300) usually present in the first decade of life with mucocutaneous candidiasis or hypoparathyroidism. This is an autosomal recessive disorder that involves the AIRE gene on chromosome 21 and presents with all or some of the following features:
- Chronic mucocutaneous candidiasis
- Hypoparathyroidism
- Adrenal failure
- Gonadal failure
- Vitiligo
- Alopecia
- Hypothyroidism
- Type 1 diabetes mellitus
- Pernicious anemia
- Steatorrhea
Type 2 PGAD consists of type 1 diabetes mellitus, autoimmune thyroid disease, and adrenal failure. Individuals with this condition generally present in the second or third decades of life, although some components of the syndrome may be present in the pediatric age group. Type 2 PGAD is transmitted as an autosomal disorder with variable penetrance.
Other acquired causes of adrenal failure include the following:
- Adrenal hemorrhage[8]
- Infections (eg, tuberculosis [TB], human immunodeficiency virus [HIV] infection)
- Neoplastic destruction
- Administration of the anesthetic agent etomidate[12]
Hemochromatosis may cause either primary or secondary adrenal insufficiency (Addison disease). Among patients with thalassemia who have received multiple transfusions, iron deposition in the pituitary and/or adrenal glands may also cause adrenal insufficiency (Addison disease).
Congenital primary adrenal insufficiency
Congenital Addison disease may occur as a result of adrenal hypoplasia[13, 14, 15] or hyperplasia.
Inherited as an X-linked disorder, adrenal hypoplasia congenita (OMIM 300200) is caused by deletion or mutation of the DAX1 gene on chromosome X.[16] This is often part of a contiguous gene deletion that also involves the genes for glycerol kinase deficiency and dystrophin, resulting in elevations in serum glycerol (often measured using a triglyceride assay) and Duchenne muscular dystrophy. An alternate form, also X linked, is characterized by intrauterine growth retardation and skeletal and genital anomalies (ie, IMAGe syndrome) (OMIM 300290). A third form of adrenal hypoplasia congenita is autosomal recessive (OMIM 240200).
Congenital adrenal hyperplasia results from a deficiency of one of several enzymes required for adrenal synthesis of cortisol. Symptoms of adrenal insufficiency (Addison disease) most often develop with combined deficiencies of cortisol and aldosterone. The most prevalent form of congenital adrenal hyperplasia is caused by a deficiency in steroid 21-hydroxylase (OMIM 201910).
Lipoid adrenal hyperplasia is another rare form of adrenal insufficiency (Addison disease) caused by a mutation in the steroid acute regulatory protein (ie, STAR protein) (OMIM 201710)[17] or a mutation in the cholesterol side-chain cleavage gene (at the cytochrome P450 [CYP] 11A locus) (OMIM 118485).[18] This disease causes a defective synthesis of all adrenocortical hormones. In its complete form, the disease is lethal.
Mutations or deletions involving CYP oxidoreductase, a flavoprotein that provides electrons to various enzyme systems, results in combined deficiencies of 17-hydroxylase, 21-hydroxylase, and 17-20 lyase activities. The result is adrenal insufficiency (Addison disease), which is often accompanied by skeletal dysplasia, genital anomalies, and primary hypogonadism.[19, 20, 21]
Relative adrenal insufficiency
The term relative adrenal insufficiency (Addison disease) has been coined to describe patients with critical illness who do not appear to mount the cortisol response expected given the severity of their illness.
Some patients developed adrenal insufficiency (Addison disease) after exposure to etomidate, an agent known to interfere with cortisol synthesis.[12] Early reports indicated improvements in outcome when such patients were provided with glucocorticoids at stress doses. Subsequent studies have clearly confirmed the fact that a substantial number of patients with critical illness who have not been exposed to etomidate have low serum cortisol concentrations.[22] Some studies have found that those with very high concentrations of cortisol have a worse prognosis and a higher complication rate of secondary sepsis or intestinal perforation. Controlled trials in adults have failed to confirm the benefit of glucocorticoid replacement therapy.
Among critically ill children, a low incremental cortisol response to ACTH does not predict mortality.[23] There is still much controversy regarding how to best diagnose adrenal insufficiency in hospitalized children and adults, as well as whether and when to treat. Thus, the decision to treat a critically ill patient with glucocorticoids must be made on a case-by-case basis until further definitive evidence is available.[24]
Epidemiology
Primary adrenal insufficiency (Addison disease) is uncommon in the United States. By comparison, iatrogenic central adrenal insufficiency is a more frequent cause of morbidity and mortality, although its exact incidence is unknown. Retrospective case review in one US urban center suggests that the prevalence of adrenal insufficiency in childhood is higher than previously suspected, approximately equivalent to that of congenital adrenal hyperplasia.[25] Adrenal insufficiency (Addison disease) secondary to congenital adrenal hyperplasia occurs in approximately 1 per 16,000 infants.
Willis and Vince collected data from Coventry County, Great Britain, where the prevalence of adrenal insufficiency (Addison disease) was similarly reported as 110 cases per million persons of all ages.[26] More than 90% of cases have been attributed to autoimmune disease. An Italian study provided statistics similar to those observed in Great Britain[27] : an estimated 117 cases per million persons.
Worldwide, the most common cause of adrenal insufficiency (Addison disease) is tuberculosis (TB), with a calculated incidence of this condition caused by TB at approximately 5-6 cases per million persons per year.
Although there does not appear to be a racial predilection, sex and age-related differences have been observed. Autoimmune adrenal insufficiency (Addison disease) is more common in female individuals than in male individuals and in adults than children, whereas adrenal insufficiency due to adrenoleukodystrophy is limited to male individuals, because it is X linked.
A form of congenital adrenal hypoplasia due to a defect in DAX1 is also X-linked and, therefore, is confined to males. Secondary forms of adrenal insufficiency (Addison disease) such as those due to a deficiency of adrenocorticotropic hormone (ACTH) or corticotropin-releasing hormone (CRH), or a defect in the ACTH receptor, are equally common among male and female individuals.
Congenital causes, such as congenital adrenal hyperplasia, congenital adrenal hypoplasia, and defects in the ACTH receptor, most commonly become apparent in childhood.
Prognosis
With proper treatment and compliance, patients with adrenal insufficiency (Addison disease) can live a normal life span without limitations. However, the prognosis for an untreated patient with adrenal insufficiency (Addison disease) is poor. Some studies have found that those with very high concentrations of cortisol have a worse prognosis and a higher complication rate of secondary sepsis or intestinal perforation.
Death is a common outcome—usually from hypotension or cardiac arrhythmia secondary to hyperkalemia—unless replacement steroid therapy is begun.
Complications
Hypotension, shock, hypoglycemia, and death are the primary complications of adrenal insufficiency (Addison disease). In addition, daily oral glucocorticoid therapy may provide iatrogenic suppression of the hypothalamic-pituitary-adrenal (HPA) axis within 2 weeks. Effects can last for weeks to months, depending on the duration of exposure to pharmacologic doses of glucocorticoids. Complications of excessive glucocorticoids include the following:
- Growth failure
- Obesity
- Striae
- Osteoporosis
- Muscle weakness
- Hypertension
- Hyperglycemia
- Cataracts
Complications of excessive administration of mineralocorticoids include hypertension and hypokalemia.
Patient Education
Educate patients with adrenal insufficiency (Addison disease) and their caretakers about the consequences and potential for death if adequate replacement therapy is not provided.
Advise patients and their caretakers to immediately seek medical help if the patient becomes ill. Patients should wear or carry a medical alert tag or card at all times to help them receive appropriate emergency care if they are found unconscious.
Supplemental and injectable glucocorticoid
Patients and their caretakers should know how to administer supplemental glucocorticoid in times of illness or traumatic stress. Include education about how to administer an injectable glucocorticoid when the patient is vomiting or unable to take oral stress doses. Periodically reinforce this information, because caretakers are often reluctant to inject medications.
An intramuscular injection of hydrocortisone (eg, 25 mg for infants, 50 mg for children, 100 mg for adults) can be lifesaving in the interval before the patient receives professional medical care. If this injection is not possible, rectal hydrocortisone can be used until systemic glucocorticoids can be administered.
Dietary considerations
Patients should eat an unrestricted diet. Those with primary adrenal insufficiency (Addison disease) should have ample access to salt because of the salt wasting that occurs if their condition is untreated. Infants with primary adrenal insufficiency (Addison disease) often need 2-4 g of sodium chloride per day.
Stewart, PM. The adrenal cortex. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen RP, eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders; 2008:Chapter 14.
Orme LM, Bond JD, Humphrey MS, Zacharin MR, Downie PA, Jamsen KM. Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression. Cancer. Jul 15 2003;98(2):397-405. [Medline].
Tsigos C, Arai K, Hung W, Chrousos GP. Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest. Nov 1993;92(5):2458-61. [Medline]. [Full Text].
Clark A, Weber A. Molecular insights into inherited ACTH resistance syndromes. Trends Endocrinol Metab. 1994;5:209-14. [Full Text].
Handschug K, Sperling S, Yoon SJ, Hennig S, Clark AJ, Huebner A. Triple A syndrome is caused by mutations in AAAS, a new WD-repeat protein gene. Hum Mol Genet. Feb 1 2001;10(3):283-90. [Medline].
Grant DB, Barnes ND, Dumic M, Ginalska-Malinowska M, Milla PJ, von Petrykowski W. Neurological and adrenal dysfunction in the adrenal insufficiency/alacrima/achalasia (3A) syndrome. Arch Dis Child. Jun 1993;68(6):779-82. [Medline].
Perry R, Kecha O, Paquette J, Huot C, Van Vliet G, Deal C. Primary adrenal insufficiency in children: twenty years experience at the Sainte-Justine Hospital, Montreal. J Clin Endocrinol Metab. Jun 2005;90(6):3243-50. [Medline]. [Full Text].
Purandare A, Godil MA, Prakash D, Parker R, Zerah M, Wilson TA. Spontaneous adrenal hemorrhage associated with transient antiphospholipid antibody in a child. Clin Pediatr (Phila). Jun 2001;40(6):347-50. [Medline].
Laureti S, Casucci G, Santeusanio F, Angeletti G, Aubourg P, Brunetti P. X-linked adrenoleukodystrophy is a frequent cause of idiopathic Addison's disease in young adult male patients. J Clin Endocrinol Metab. Feb 1996;81(2):470-4. [Medline]. [Full Text].
Korenke GC, Roth C, Krasemann E, Hufner M, Hunneman DH, Hanefeld F. Variability of endocrinological dysfunction in 55 patients with X-linked adrenoleucodystrophy: clinical, laboratory and genetic findings. Eur J Endocrinol. Jul 1997;137(1):40-7. [Medline]. [Full Text].
Andersson HC, Frentz J, Martínez JE, Tuck-Muller CM, Bellizaire J. Adrenal insufficiency in Smith-Lemli-Opitz syndrome. Am J Med Genet. Feb 19 1999;82(5):382-4. [Medline].
Vinclair M, Broux C, Faure P, et al. Duration of adrenal inhibition following a single dose of etomidate in critically ill patients. Intensive Care Med. Apr 2008;34(4):714-9. [Medline].
Peter M, Viemann M, Partsch CJ, Sippell WG. Congenital adrenal hypoplasia: clinical spectrum, experience with hormonal diagnosis, and report on new point mutations of the DAX-1 gene. J Clin Endocrinol Metab. Aug 1998;83(8):2666-74. [Medline]. [Full Text].
Ferraz-de-Souza B, Achermann JC. Disorders of adrenal development. Endocr Dev. 2008;13:19-32. [Medline].
Kempna P, Fluck CE. Adrenal gland development and defects. Best Pract Res Clin Endocrinol Metab. Feb 2008;22(1):77-93. [Medline].
Lalli E, Sassone-Corsi P. DAX-1 and the adrenal cortex. Curr Opin Endocrinol Diabetes. 1999;6:185-90. [Full Text].
Baker BY, Lin L, Kim CJ, et al. Nonclassic congenital lipoid adrenal hyperplasia: a new disorder of the steroidogenic acute regulatory protein with very late presentation and normal male genitalia. J Clin Endocrinol Metab. Dec 2006;91(12):4781-5. [Medline].
Kim CJ, Lin L, Huang N, et al. Severe combined adrenal and gonadal deficiency caused by novel mutations in the cholesterol side chain cleavage enzyme, P450scc. J Clin Endocrinol Metab. Mar 2008;93(3):696-702. [Medline].
Miller WL. Minireview: regulation of steroidogenesis by electron transfer. Endocrinology. Jun 2005;146(6):2544-50. [Medline].
Pandey AV, Fluck CE, Huang N, Tajima T, Fujieda K, Miller WL. P450 oxidoreductase deficiency: a new disorder of steroidogenesis affecting all microsomal P450 enzymes. Endocr Res. Nov 2004;30(4):881-8. [Medline].
Fluck CE, Tajima T, Pandey AV, Arlt W, Okuhara K, Verge CF. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome. Nat Genet. Mar 2004;36(3):228-30. [Medline].
Lamberts SW, Bruining HA, de Jong FH. Corticosteroid therapy in severe illness. N Engl J Med. Oct 30 1997;337(18):1285-92. [Medline].
Pizarro CF, Troster EJ, Damiani D, Carcillo JA. Absolute and relative adrenal insufficiency in children with septic shock. Crit Care Med. Apr 2005;33(4):855-9. [Medline].
Fleseriu M, Loriaux DL. "Relative" adrenal insufficiency in critical illness. Endocr Pract. Sep-Oct 2009;15(6):632-40. [Medline].
Hsieh S, White PC. Presentation of primary adrenal insufficiency in childhood. J Clin Endocrinol Metab. Jun 2011;96(6):E925-8. [Medline].
Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. Postgrad Med J. May 1997;73(859):286-8. [Medline].
Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison's disease underestimated? [letter]. J Clin Endocrinol Metab. May 1999;84(5):1762. [Medline]. [Full Text].
Arlt W, Allolio B. Adrenal insufficiency. Lancet. May 31 2003;361(9372):1881-93. [Medline].
Besser GM, Thorner MO. Adrenal insufficiency. In: Clinical Endocrinology. [CD-ROM]. St Louis, Mo: Mosby-Year Book; 1996.
Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. Jan 2008;36(1):296-327. [Medline].
Clark L, Preissig C, Rigby MR, Bowyer F. Endocrine issues in the pediatric intensive care unit. Pediatr Clin North Am. Jun 2008;55(3):805-33, xiii. [Medline].
Kamoi K, Tamura T, Tanaka K, Ishibashi M, Yamaji T. Hyponatremia and osmoregulation of thirst and vasopressin secretion in patients with adrenal insufficiency. J Clin Endocrinol Metab. Dec 1993;77(6):1584-8. [Medline]. [Full Text].
Lashansky G, Saenger P, Fishman K, Gautier T, Mayes D, Berg G. Normative data for adrenal steroidogenesis in a healthy pediatric population: age- and sex-related changes after adrenocorticotropin stimulation. J Clin Endocrinol Metab. Sep 1991;73(3):674-86. [Medline].
Neary N, Nieman L. Adrenal insufficiency: etiology, diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. Apr 6 2010;[Medline].
Heckmann M, Hartmann MF, Kampschulte B, Gack H, Bodeker RH, Gortner L. Cortisol production rates in preterm infants in relation to growth and illness: a noninvasive prospective study using gas chromatography-mass spectrometry. J Clin Endocrinol Metab. Oct 2005;90(10):5737-42. [Medline]. [Full Text].
Kronenberg HM, Melmed S, Polonsky KS, Larson PR, eds. Williams Textbook of Endocrinology. 11th ed. Philadelphia, PA: Saunders; 2008:229.
Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic-pituitary- adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab. Nov 2008;93(11):4245-53. [Medline].
Thaler LM. Comment on the low-dose corticotropin stimulation test is more sensitive than the high-dose test. [letter]. J Clin Endocrinol Metab. Dec 1998;83(12):4530-1; author reply 4532-3. [Medline].
Tordjman K, Jaffe A, Greenman Y, Stern N. Comments on the comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab. Dec 1998;83(12):4530; author reply 4532-3. [Medline].
Mayenknecht J, Diederich S, Bahr V, Plockinger U, Oelkers W. Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease. J Clin Endocrinol Metab. May 1998;83(5):1558-62. [Medline]. [Full Text].
Dickstein G. Commentary to the article: Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease [letter]. J Clin Endocrinol Metab. Dec 1998;83(12):4531-3. [Medline]. [Full Text].
Neary N, Nieman L. Adrenal insufficiency: etiology, diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes. Jun 2010;17(3):217-23. [Medline]. [Full Text].
Libe R, Barbetta L, Dall'Asta C, et al. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. J Endocrinol Invest. Sep 2004;27(8):736-41. [Medline].
van Thiel SW, Romijn JA, Pereira AM, et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial. J Clin Endocrinol Metab. Jun 2005;90(6):3295-303. [Medline].
Merke DP, Chrousos GP, Eisenhofer G, et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med. Nov 9 2000;343(19):1362-8. [Medline].
Coutant R, Maurey H, Rouleau S, et al. Defect in epinephrine production in children with craniopharyngioma: functional or organic origin?. J Clin Endocrinol Metab. Dec 2003;88(12):5969-75. [Medline].
Frank GR, Speiser PW, Griffin KJ, Stratakis CA. Safety of medications and hormones used in pediatric endocrinology: adrenal. Pediatr Endocrinol Rev. Nov 2004;2 Suppl 1:134-45. [Medline].

